Arbidol is active against influenza, ARVI and coronavirus viruses
Powder for oral suspension - 30 EUR
50mg N10tab - 17 EUR
50mg N20tab - 27 EUR
100mg N20caps - 40 EUR
100mg N40caps - 75 EUR
max200mg N10caps - 37 EUR
The drug Arbidol is registered by the Ministry of Health of the Russian Federation in the manner prescribed by Russian law. When registering the drug in the registration dossier, the manufacturer provided all the necessary documents, including reports confirming the effectiveness and safety of the drug according to the indications for use indicated in the instructions.
From the moment of development to the present, more than 120 preclinical and clinical trials have been carried out regarding the drug Arbidol, about a third of them are foreign (USA, Australia, China, France, etc.). The results of the research are published in peer-reviewed scientific journals(list of scientific articles attached). You can also get acquainted with publications regarding the drug Arbidol on available information resources of scientific publications, for example, elibrary.ru and www.ncbi.nlm.nih.gov/pubmed.
Based on the available evidence, the drug Arbidol is included in the standards and recommendations for the treatment of influenza and acute respiratory viral infections of various etiologies in adults and children, including those approved by the Ministry of Health of the Russian Federation, with evidence of reliability level I-II, which means that the recommendations for the use of the drug Arbidol in these diseases, they are based on the results of studies of a high level of evidence - randomized controlled trials and systematic reviews.
Arbidol (INN umifenovir, all forms of release) is indicated for the prevention and treatment of influenza and other acute respiratory viral infections (ARVI) in adults and children. According to the medical instructions, Arbidol (umifenovir) is active against influenza A and B viruses (Influenza virus A, B), as well as Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, associated with severe acute respiratory syndrome (SARS), rhinovirus (Rhinovirus ), adenovirus (Adenovirus), respiratory syncytial virus (Pneumovirus) and parainfluenza virus (Paramyxovirus).
The possibility of using the drug Arbidol in acute respiratory viral infections of various etiologies is due to the universal mechanism of action of the drug, which consists in blocking the stage of penetration of viruses into the cell (virus fusion). Due to this mechanism of action, the drug Arbidol has a wide range of antiviral activity against viruses that cause various acute respiratory infections, including viruses from the Coronaviridae family, as evidenced by numerous studies.